Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

NCT02587221 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

6790

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
BIOLOGICAL: Non-Influenza Comparator (Boostrix)

Sponsor

Seqirus